Lamivudine Maintenance Beyond One Year After Hbeag Seroconversion Is A Major Factor for Sustained Virologic Response in Hbeag-Positive Chronic Hepatitis B

Abstract

The lamivudine-induced virologic response was durable in patients under 40 years old and those receiving lamivudine for more than 12 months after HBeAg clearance or seroconversion. Age and additional treatment were major predictive factors for SVR.